01
M&A Advisory
We advise on the full deal lifecycle - from target identification to post-merger integration. We have completed 17 acquisitions. We know where deals break down and how to prevent them.
Operator-augmented AI for biopharma strategy
Operator-Led Biopharma Consulting Transforming Vision into Value
We help biopharma companies grow faster and execute better. Most consultants have never run a company. Our Founder, Doug Drysdale, has. He has led 17 acquisitions, raised USD 4B+, and served as CEO of Alvogen and Cybin, among others. That experience is what you get when you work with Katogen. Not a junior team running a framework. An operator who has solved your problem before.
Operator judgment
The Katogen Difference
There is a difference between advising on a deal and closing one. Katogen is built on 35 years of building, not just advising. Every recommendation we make is grounded in real decisions, real companies, and real consequences. We have navigated product launches, capital raises, M&A integrations, and board-level crises. We know what works and what fails - because we have lived both.
Capabilities
What We Do
Katogen works across six areas where biopharma companies most often need experienced guidance.
02
Capital Strategy
We help you structure and execute capital raises that match your stage and risk profile. USD 4B+ raised across the sector. Debt, equity, licensing, and partnership structures.
03
Product Commercialisation
Launching a product is complex. Payer strategy, PBM negotiations, formulary access, and pricing decisions all occur simultaneously. We have done this before. We help you avoid the mistakes that cost revenue at launch.
04
Board Advisory
We provide an independent board-level perspective for companies navigating strategic decisions, governance challenges, or leadership transitions.
05
Fractional C-Suite
Sometimes you need an experienced operator in the room - not a report. We provide fractional CEO and C-suite leadership for companies at critical inflection points.
06
Strategic Consulting
From early-stage to scale, we advise on the decisions that determine whether a biopharma company grows, stalls, or closes a deal.
Leadership
Fractional Executive, Board & Advisory Roles
Not every company needs a full-time hire. Some challenges need an experienced operator for a defined period, then done. Katogen provides fractional C-suite and board-level leadership for growth-stage life sciences companies at critical inflection points.
This works well for companies that are:
- Navigating a major M&A transaction.
- Preparing for a capital raise.
- Managing a company turnaround.
- Building a board ahead of an IPO.
- Filling an interim leadership gap
Context
The Biopharma Landscape
The biopharma sector is under pressure right now. Patent cliffs are accelerating. M&A activity is increasing. Capital markets are tighter than they have been in a decade. Competition is intensifying across every major therapeutic area. Companies that move fast with the right strategy will capture significant value. Companies that move slowly - or with the wrong advice - will not. Katogen exists for the companies that want to move fast and get it right.
Ready To Move From Vision To Value?
If you are navigating a deal, a capital raise, or a growth challenge - let's talk. Engagements are structured as project-based consulting, retained advisory, or fractional executive arrangements. Every engagement starts with a direct conversation with our Founder. No sales team. No junior handoff. Just an operator who has done this before.